Abstract: The present invention relates to a compound comprising a hydrophobic moiety, a linker and N-containing moiety. The present invention also relates to the method of synthesizing the compound and the use of the compound as an antibiotic or an adjuvant for an antibiotic.

Abstract: Disclosed herein is an aqueous composition comprising 0.001-0.1% (w/v) atropine or a salt thereof, a water-soluble polymer, and buffer (1), which is at a pH range of 6 or lower, wherein the buffer (1) is at least one selected from the group consisting of a phosphate buffer, an aminocarboxylate buffer, a carbonate buffer, an acetate buffer, a tartrate buffer, a borate buffer, and trometamol.

Abstract: The present invention relates to a compound comprising a hydrophobic moiety, a linker and N-containing moiety. The present invention also relates to the method of synthesizing the compound and the use of the compound as an antibiotic or an adjuvant for an antibiotic.

Abstract: Methods of preventing or delaying onset of myopia in pre-myopic patients and also methods of reducing or preventing progression of myopia in patients having low myopia through the use of compositions comprising less than 0.025% of atropine are disclosed.

Abstract: Disclosed herein is an aqueous composition comprising 0.001-0.1% (w/v) atropine or a salt thereof, a water-soluble polymer, and buffer (I), which is at a pH range of 6 or lower, wherein the buffer (I) is at least one selected from the group consisting of a phosphate buffer, an aminocarboxylate buffer, a carbonate buffer, an acetate buffer, a tartrate buffer, a borate buffer, and trometamol.

Abstract: The present invention relates to a method for predicting a response to a treatment of an eye disease on the basis of proteome changes. The invention also relates to a kit for use the method.

Abstract: Methods of preventing or delaying onset of myopia in pre-myopic patients and also methods of reducing or preventing progression of myopia in patients having low myopia through the use of compositions comprising less than 0.025% of atropine are disclosed.

Abstract: In various embodiments, device for determining a condition of an organ of either a human or an animal may be provided. The device may include a first optical source and a second optical source. The device may also include a detector. The device may additionally include a lens system. The device may further include a switching mechanism configured to switch between an optical examination mode and a Raman mode. The lens system during the optical examination mode may be configured to direct a first light emitted from the first optical source. The lens system during the Raman mode may be configured to direct a second light emitted from the second optical source. The lens systems during the Raman mode may be further configured to direct a third light to the detector.

Abstract: In various embodiments, a device for determining a condition of an organ of either a human or an animal may be provided. The device may include a first optical source and a second optical source. The device may also include a detector. The device may additionally include a lens system. The device may further include a switching mechanism configured to switch between an optical examination mode and a Raman mode. The lens system during the optical examination mode may be configured to direct a first light emitted from the first optical source. The lens system during the Raman mode may be configured to direct a second light emitted from the second optical source. The lens systems during the Raman mode may be further configured to direct a third light to the detector.

Abstract: In various embodiments, device for determining a condition of an organ of either a human or an animal may be provided. The device may include a first optical source and a second optical source. The device may also include a detector. The device may additionally include a lens system. The device may further include a switching mechanism configured to switch between an optical examination mode and a Raman mode. The lens system during the optical examination mode may be configured to direct a first light emitted from the first optical source. The lens system during the Raman mode may be configured to direct a second light emitted from the second optical source. The lens systems during the Raman mode may be further configured to direct a third light to the detector.

Abstract: An isolated peptide tetramer includes the formula [(RGRKVVRR)2K]2KK and its derivatives thereof. The derivatives may include at least one amino acid substitution, at least one amino acid deletion, a rearrangement of the peptide monomer and/or at least one non-proteogenic amino acid modification in at least one peptide monomer. The isolated peptide tetramer and derivatives thereof have antimicrobial (antibacterial, antifungal and/or anti-protozoan) properties.

Abstract: There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.

Abstract: The present invention relates to diagnosis and/or treatment of medical conditions. The present invention relates to new method of diagnosing dry mucosa condition in a subject. The condition may be dry eye. The present invention also provides a method to monitor the efficacy of a treatment of a dry mucosa condition, a method of treating a dry mucosa condition and/or a diagnostic kit for a dry mucosa condition.

Abstract: There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.

Abstract: The invention relates to materials and methods for producing equivalents of tissues of the ocular surface, especially conjunctival tissue equivalents. The method of the invention involves biopsy of an appropriate tissue, primary culture in a certain medium, proliferative culture in a second medium, and differentiative culture in a third medium. The tissue equivalents are typically grown upon a substrate, typically amniotic membrane, which provides ease of handling as one advantage.

Abstract: The present invention relates to diagnosis and/or treatment of medical conditions. The present invention relates to new method of diagnosing dry mucosa condition in a subject. The condition may be dry eye. The present invention also provides a method to monitor the efficacy of a treatment of a dry mucosa condition, a method of treating a dry mucosa condition and/or a diagnostic kit for a dry mucosa condition.

Abstract: The invention relates to materials and methods for producing equivalents of tissues of the ocular surface, especially conjunctival tissue equivalents. The method of the invention involves biopsy of an appropriate tissue, primary culture in a certain medium, proliferative culture in a second medium, and differentiative culture in a third medium. The tissue equivalents are typically grown upon a substrate, typically amniotic membrane, which provides ease of handling as one advantage.

Abstract: The invention relates to materials and methods for producing equivalents of tissues of the ocular surface, especially conjunctival tissue equivalents. The method of the invention involves biopsy of an appropriate tissue, primary culture in a certain medium, proliferative culture in a second medium, and differentiative culture in a third medium. The tissue equivalents are typically grown upon a substrate, typically amniotic membrane, which provides ease of handling as one advantage.

Abstract: The invention relates to materials and methods for producing equivalents of tissues of the ocular surface, especially conjunctival tissue equivalents. The method of the invention involves biopsy of an appropriate tissue, primary culture in a certain medium, proliferative culture in a second medium, and differentiative culture in a third medium. The tissue equivalents are typically grown upon a substrate, typically amniotic membrane, which provides ease of handling as one advantage.